• linkedin
  • Increase Font
  • Sharebar

    Uro Pipeline: FDA accepts two supplemental applications for mUC agent


    Combination RCC treatment yields positive phase II results

    Roche has announced positive results from a phase II study that compared atezolizumab (Tecentriq) in combination with bevacizumab (Avastin) and atezolizumab monotherapy in comparison to sunitinib (Sutent) alone in people with untreated metastatic renal cell carcinoma (RCC). The global, multicenter, open-label, randomized phase II study found that treatment with atezolizumab plus bevacizumab led to a 36% reduction in disease progression or death compared to sunitinib monotherapy. The study included 305 metastatic RCC patients who had been previously untreated. Separately, Roche is involved with a phase III study evaluating atezolizumab in combination with bevacizumab against sunitinib in patients with previously untreated metastatic RCC.


    Infertility tool found accurate for predicting sperm quality

    Aytu Bioscience has announced the publication of a study demonstrating the clinical utility of the company's MiOXSYS System for assessing the level of oxidative stress in semen as an aid in the diagnosis of infertility in men. The article appears online in Urology ahead of print. The MiOXSYS System measures oxidation-reduction potential (ORP), which comprehensively measures oxidative stress by simultaneously accounting for all the known and unknown oxidants and antioxidants in the semen sample. Results of the study established oxidative stress as a key mechanism in patients suffering from oligozoospermia and that ORP can serve as an indicator of sperm quality over time. Aytu has obtained CE marking for commercialization in Europe, but is currently pursuing an FDA clearance pathway in the United States.

    Next: Study to examine effects of vaccine/immunotherapy combo in mUC

    Ben Schwartz
    Ben Schwartz is Associate Editor, Contemporary OB/GYN.


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available